A specific phosphorylation-dependent conformational switch in SARS-CoV-2 nucleocapsid protein inhibits RNA binding.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
02 Aug 2024
Historique:
medline: 2 8 2024
pubmed: 2 8 2024
entrez: 2 8 2024
Statut: ppublish

Résumé

The nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 encapsidates the viral genome and is essential for viral function. The central disordered domain comprises a serine-arginine-rich (SR) region that is hyperphosphorylated in infected cells. This modification regulates function, although mechanistic details remain unknown. We use nuclear magnetic resonance to follow structural changes occurring during hyperphosphorylation by serine arginine protein kinase 1, glycogen synthase kinase 3, and casein kinase 1, that abolishes interaction with RNA. When eight approximately uniformly distributed sites have been phosphorylated, the SR domain binds the same interface as single-stranded RNA, resulting in complete inhibition of RNA binding. Phosphorylation by protein kinase A does not prevent RNA binding, indicating that the pattern resulting from physiologically relevant kinases is specific for inhibition. Long-range contacts between the RNA binding, linker, and dimerization domains are abrogated, phenomena possibly related to genome packaging and unpackaging. This study provides insight into the recruitment of specific host kinases to regulate viral function.

Identifiants

pubmed: 39093972
doi: 10.1126/sciadv.aax2323
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
RNA, Viral 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
Nucleocapsid Proteins 0
Phosphoproteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaax2323

Auteurs

Maiia Botova (M)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Aldo R Camacho-Zarco (AR)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Jacqueline Tognetti (J)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Luiza Mamigonian Bessa (LM)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Serafima Guseva (S)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Emmi Mikkola (E)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Nicola Salvi (N)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Damien Maurin (D)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Torsten Herrmann (T)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Martin Blackledge (M)

Université Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH